On September 15, Teva Pharmaceutical rose 5.07% in regular trading, trading at $38.94/share, with turnover of $38.411 million.

On the news front, Teva Pharmaceutical announced that its ordinary shares have officially begun direct trading on the New York Stock Exchange, completing the transition from its American Depositary Shares program. The stock continues to trade under the ticker TEVA on both the NYSE and the Tel Aviv Stock Exchange. The company stated that the direct listing is expected to expand investor access and strengthen its position in US capital markets.

Supporting the positive momentum, the company recently priced approximately $4.9 billion in senior notes across five tranches of euro- and dollar-denominated debt, with proceeds earmarked for redeeming existing obligations and general corporate purposes. Additionally, Leerink Partners initiated coverage with an Outperform rating and a $45 price target, while the analyst consensus maintains a buy rating with a mean target of $41.89.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products globally, with key focus areas in central nervous system, respiratory, and oncology.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)